Skip to main content

Recombinant Mouse VSIG4 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 4674-VS

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
4674-VS-050

Key Product Details

Source

NS0

Accession #

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived mouse VSIG4 protein
Mouse VSIG4
(His20-Pro187)
Accession # NP_808457
IEGRMDP Mouse IgG2A
(Glu98-Lys330)
N-terminus C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

His20

Predicted Molecular Mass

46 kDa (monomer)

SDS-PAGE

60-65 kDa, reducing conditions

Activity

Measured by its ability to inhibit anti-CD3-induced proliferation of splenic T lymphocytes. Vogt, L. et al. (2006) J. Clin. Invest. 116:2817.
The presence of immobilized Recombinant Mouse VSIG4 Fc Chimera inhibited the anti-CD3 response by ≥50%. The ED50 for this effect is 1.25‑5 µg/mL.

Scientific Data Images for Recombinant Mouse VSIG4 Fc Chimera Protein, CF

Recombinant Mouse VSIG4 Fc Chimera Protein Bioactivity

Recombinant Mouse VSIG4 Fc Chimera Protein Bioactivity

Recombinant Mouse VSIG4 Fc Chimera (Catalog # 4674-VS) inhibits anti-CD3-induced proliferation of mouse splenic T lymphocytes. The presence of immobilized Recombinant Mouse VSIG4 Fc Chimera inhibits the anti-CD3 response by ≥50%. The ED50 for this effect is 1.25‑5 µg/mL.

Formulation, Preparation and Storage

4674-VS
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 200 μg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VSIG4

Mouse VSIG4 (V-set and immunoglobulin domain containing 4), also known as CRIg and Z39IG, is a 45 kDa, type I transmembrane glycoprotein that is a B7 family-related protein and an Ig superfamily member (1, 2). Mouse VSIG4 is synthesized as a 280 amino acid (aa) precursor that contains a signal sequence, an IgV-type immunological domain (aa 36-115), one potential N-linked glycosylation site, and a single transmembrane domain (2). The IgV domain of mouse VSIG4 shares 86% and 80% aa sequence identity with the IgV domains of rat and human VSIG4, respectively. Quantitative PCR reveals that VSIG4 mRNA is expressed at high levels in the liver, dendritic cells, neutrophils, and macrophages, and at lower levels in the lung, heart, spleen, and lymph nodes (1). No VSIG4 expression appears to be present in T and B cells (1). The use of polyclonal rabbit serum against the extracellular domain of VSIG4 demonstrates that VSIG4 is specifically expressed on naïve resting tissue macrophages, and that the expression is downregulated or lost upon activation (1). Furthermore, histological analysis shows expression of VSIG4+ macrophages only in the liver, thymic medulla, and heart (1). VSIG4 macrophages are not detected in the intestines, kidney, skeletal muscle, lymph node, splenic white pulp, lung, or brain (1). Studies show that VSIG4/Fc Chimera strongly inhibits proliferation of anti-CD3 as well as anti-CD3/anti-CD28-stimulated T cells (1). Indeed, VSIG4 functions as a negative regulator of mouse as well as human T cell activation, and may be involved in the maintenance of peripheral T cell tolerance and/or unresponsiveness (1). In addition, VSIG4’s expression on Kupffer cells is required for efficient binding and phagocytosis of complement C3 opsonized particles (2). VSIG4 acts as a macrophage complement receptor by binding complement fragments C3b and iC3b (2). VSIG4 binding to C3b inhibits complement activation through the alternative pathway, making it a potent suppressor of established inflammation (3, 4).

References

  1. Vogt, L. et al. (2006) J. Clin. Invest. 116:2817.
  2. Helmy, K. et al. (2006) Cell 124:915.
  3. Katschke, K.J. et al. (2007) J. Exp. Med. 204:1319.
  4. Wiesmann, C. et al. (2006) Nature 444:217.

Long Name

V-Set and Immunoglobulin Domain Containing 4

Alternate Names

Z39IG

Entrez Gene IDs

11326 (Human); 278180 (Mouse); 312102 (Rat); 102144784 (Cynomolgus Monkey)

Gene Symbol

VSIG4

UniProt

Additional VSIG4 Products

Product Documents for Recombinant Mouse VSIG4 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Mouse VSIG4 Fc Chimera Protein, CF

For research use only

Loading...
Loading...
Loading...